What is the current status of adjuvant therapy in resected pancreatic cancer?

FAQ Library published on November 9, 2016
Download Transcript Download Audio
Margaret A. Tempero, MD
Professor of Medicine
Department of Medicine
Division of Hematology and Oncology
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

What is the current status of adjuvant therapy in resected pancreatic cancer?
Welcome to Partners in Pancreatic Cancer. My name is Margaret Tempero and I am a medical oncologist who specializes in the care of patients with pancreatic cancer. You might be wondering about the current status of adjuvant therapy in patients who undergo resection for pancreatic cancer. First of all, we know that adjuvant therapy is very, very important and improves survival. Traditionally we have used gemcitabine, 5FU, and sometimes radiation, and we really have not moved the bar in terms of advancing the survival after resection. Right now, a lot of thought is being given to using multiagent chemotherapy in the postoperative adjuvant setting, as well as to neoadjuvant therapy to improve the chance of an R0 resection, that is a margin negative resection, which will get more patients successfully into the operating room. Thank you for viewing this activity. For additional resources, please be sure to view the other educational activities on PartnersinPancreaticCancer.com.
Last modified: October 25, 2016
Related Items by Author
Are there any types of pancreatic cancer patients who should NOT be referred for a clinical trial?
Margaret A. Tempero, MD
FAQ Library published on June 7, 2016
Do patients who have surgical resection need additional treatment?
Margaret A. Tempero, MD
FAQ Library published on February 10, 2016
What are the emerging therapies that will impact our practice in the near future?
Margaret A. Tempero, MD
FAQ Library published on March 21, 2014 in Assess & Monitor
What are the pros and cons of treatment and who should be treated?
Margaret A. Tempero, MD
FAQ Library published on November 22, 2013 in Practice
Why should patients consider treatment in a center of excellence?
Margaret A. Tempero, MD
FAQ Library published on September 27, 2013 in Practice
What is the best imaging study with which to evaluate the pancreas?
Margaret A. Tempero, MD
FAQ Library published on August 6, 2013 in Assess & Monitor
What aspects of a patient’s history or signs and symptoms should prompt a pancreatic cancer work-up?
Margaret A. Tempero, MD
FAQ Library published on May 31, 2013

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved